Mechanisms responsible for cardiac and skeletal muscle energetic impairment in type 1 diabetes

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-002638-39-GB

Enrollment

Registered

2006-09-18

Start date

2006-08-23

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Interventions

Product Name: Pexsig Pharmaceutical Form: Tablet INN or Proposed INN: Perhexilene CAS Number: 6724-5-34 Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 100-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Type I diabetes (WHO definition) 2.HbA1C =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients: 1.Patients 250) or diabetic nephropathy 7.Concomitant use of Amiodarone, Quinidine, Haloperidol or Selective serotonin (5HT) uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6 enzyme 8.Patients on statin therapy for primary dyslipidemia. 9.Patients with recurrent hypoglycaemia 10.Women of child bearing age who are not using effective contraception (or if pregnancy test positive)

Design outcomes

Primary

Measure	Time frame
Main Objective: The primary end point of the study will be the change in cardiac PCr/ATP ratio.;Secondary Objective: Secondary end points of the study will be changes in PCr recovery half time in skeletal muscle after exercise, mitochondrial coupling ratio in skeletal muscle, UCP expression in skeletal muscle and VO2max on exercise testing.;Primary end point(s): PCr/ATP ratio in the heart.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026